A comparison of the SMAD2 mutations with clinical characteristics of cancers did not reveal an association of mutations with cancer stages, but p.S464Ter showed a trend toward decreased OS of patients with the mutations (Figure 5D ) in pan-cancer and in the individual cancers with >1 p.S464Ter occurrence in informative samples.
2
—
—
The sentences
TNRC6A in STAD and DICER1 in SKCM and UCEC (nominal P > 0.005), but these overmutations are only nominally significant.